*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. With the publication on the same day of a decision and an opinion, the Competition Authority (the "Authority") closes a rich year for the pharmaceutical sector in 2013. The European Commission adopted two decisions (not yet published) on pay-for-delay in the Lundbeckcases of 19 June 2013. (IP/13/563) and more recently Johnson & Johnson and Novartis on 10 December 2013. (IP/13/1233). The Commission also published its fourth report on out-of-court settlements between originator and generic pharmaceutical companies in 2012 (IP/13/1228). Similarly, the Authority sanctioned Sanofi in the Plavix case of May 14, 2013 (see Decision No. 13-D-11 of May 14,
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.